1                                 The RP2D was durvalumab 1,500 mg every 4 weeks with olaparib 300 mg t

2 omplications arising from myasthenia gravis (durvalumab 10 mg/kg every 4 weeks plus tremelimumab 1 mg

3                                              Durvalumab 20 mg/kg every 4 weeks plus tremelimumab 1 mg

4 tremelimumab 1 mg/kg), pericardial effusion (durvalumab 20 mg/kg every 4 weeks plus tremelimumab 1 mg

5 imumab 1 mg/kg), and neuromuscular disorder (durvalumab 20 mg/kg every 4 weeks plus tremelimumab 3 mg

6 ed dose was exceeded in the cohort receiving durvalumab 20 mg/kg every 4 weeks plus tremelimumab 3 mg

7 ation treatment with the anti-PD-L1 antibody durvalumab and the anti-CTLA-4 antibody tremelimumab mig

8                                              Durvalumab demonstrated a manageable safety profile and

9 tients and Methods This phase I study tested durvalumab doublets in parallel 3 + 3 dose escalations.

10                             We gave patients durvalumab in doses of 3 mg/kg, 10 mg/kg, 15 mg/kg, or 2

11                                  Exposure to durvalumab increased cediranib area under the curve and

12                                              Durvalumab (MEDI4736, 10 mg/kg every 2 weeks) was admini

13 programmed death-ligand 1 (PD-L1) inhibitor, durvalumab, olaparib, or cediranib combinations are tole

14 e seen in 12 evaluable patients who received durvalumab plus cediranib, for a 50% response rate and a

15    The RP2Ds of durvalumab plus olaparib and durvalumab plus intermittent cediranib are tolerable and

16                                              Durvalumab plus intermittent cediranib grade 3 and 4 AEs

17                                 The RP2Ds of durvalumab plus olaparib and durvalumab plus intermitten

18  months]) were seen in patients who received durvalumab plus olaparib, yielding an 83% disease contro

19  No dose-limiting toxicity was recorded with durvalumab plus olaparib.

20                           We aimed to assess durvalumab plus tremelimumab in patients with advanced s

21                                              Durvalumab was administered at 10 mg/kg every 2 weeks or